Recursion Pharmaceuticals: Pay

Recursion Pharmaceuticals paid its 3 named executives $16.3M in total in FY2025 (Dec). CEO Najat Khan was paid $5.3M of that.

Pay$100 in the stock at the end of FY23 → $41
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Chris Gibson, Ph.D.former Chief Executive Officer and President and current Chair of the Board
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Najat Khancurrent Chief Executive Officer and President
FY2025 (Dec)
FY2024 (Dec)
2 years
Ben TaylorChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $9.5M. CEO pay of Recursion Pharmaceuticals for that year is not on file.

  1. 1C3.ai
  2. 2BridgeBio Pharma
  3. 3Intapp
  4. 4Twist Bioscience
  5. 5IDEAYA Biosciences
  6. 6Adaptive Biotechnologies
  7. 7Repligen
  8. 8Denali Therapeutics
  9. 9Schrodinger
  10. 10Recursion PharmaceuticalsNot disclosed
  11. 11AbCellera BiologicsNot disclosed
  12. 12CertaraNot disclosed
  13. 13Cytek BiosciencesNot disclosed
  14. 14Dyne TherapeuticsNot disclosed
  15. 15Relay TherapeuticsNot disclosed
  16. 16Rocket PharmaceuticalsNot disclosed
  17. 17Soundhound AiNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.